Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

1. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.Transplantation and cellular therapy · 2021
   Article
2. Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis.Therapeutic advances in hematology · 2021
   Article
3. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.Journal of hematology & oncology · 2020
   Review
4. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.International journal of molecular sciences · 2019
   Review
5. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.JAMA oncology · 2019
   Article
6. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.Bone marrow transplantation · 2018
   Review
7. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
   Article
8. Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.Pharmaceuticals (Basel, Switzerland) · 2017
   Review
9. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2015
   Article
10. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Bone marrow transplantation · 2015
    Review
11. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.World journal of transplantation · 2015
    Review
12. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.Leukemia · 2015
    Article
13. Blood and marrow transplant clinical trials network state of the Science Symposium 2014.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
    Article
14. Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers.Chemotherapy research and practice · 2015
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as